Changeflow GovPing Pharma & Drug Safety Lipid Triglyceride Surfactant Composition, Pate...
Routine Notice Added Final

Lipid Triglyceride Surfactant Composition, Patent US12599580B2

Favicon for changeflow.com USPTO Patent Grants - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO granted patent US12599580B2 to BASF AS on April 14, 2026, covering compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, a triglyceride, and a surfactant, as well as methods of using the same in self-emulsifying drug delivery systems such as SEDDS, SMEDDS, or SNEDDS. The patent contains 20 claims.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued patent US12599580B2 to BASF AS on April 14, 2026, granting exclusive intellectual property rights to a pharmaceutical composition containing 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid (or ester derivative or salt), a triglyceride, and a surfactant, along with methods of using the composition.

For pharmaceutical manufacturers and drug developers, this patent establishes BASF's proprietary position in self-emulsifying drug delivery system technologies. Competitors seeking to develop similar SEDDS, SMEDDS, or SNEDDS formulations may need to obtain licensing or design around the protected composition claims.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same

Grant US12599580B2 Kind: B2 Apr 14, 2026

Assignee

BASF AS

Inventors

Svein Olaf Hustvedt, Preben Houlberg Olesen, Annette Müllertz

Abstract

Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as SEDDS, SMEDDS, or SNEDDS comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid.

CPC Classifications

A61K 31/202

Filing Date

2022-05-05

Application No.

17737761

Claims

20

View original document →

Get daily alerts for USPTO Patent Grants - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12599580B2

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant IP licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!